ChemicalBook > CAS DataBase List > Atazanavir

Atazanavir

Product Name
Atazanavir
CAS No.
198904-31-3
Chemical Name
Atazanavir
Synonyms
Atv;CS-534;CS-2210;atazanvir;EOS-60363;Atazanavir;Aids057755;Aids-057755;Latazanavir;Atazanavir Base
CBNumber
CB0500863
Molecular Formula
C38H52N6O7
Formula Weight
704.86
MOL File
198904-31-3.mol
More
Less

Atazanavir Property

Melting point:
207-2090C
alpha 
D -47° (c = 1 in ethanol)
Density 
1.178±0.06 g/cm3(Predicted)
storage temp. 
-20°C
pka
11.11±0.46(Predicted)
form 
powder
color 
white to beige
CAS DataBase Reference
198904-31-3
More
Less

Safety

Hazardous Substances Data
198904-31-3(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
11733
Product name
Atazanavir
Purity
≥95%
Packaging
1mg
Price
$35
Updated
2021/03/22
Cayman Chemical
Product number
11733
Product name
Atazanavir
Purity
≥95%
Packaging
5mg
Price
$105
Updated
2021/03/22
More
Less

Atazanavir Chemical Properties,Usage,Production

Description

Atazanavir is an inhibitor of human immunodeficiency virus type 1 (HIV-1) protease, an enzyme that is essential for the processing of Gag and Gag-Pol polyproteins into structural and enzymatic proteins required for viral replication. It has a similar pharmacophore motif to the other six widely marketed HIV protease inhibitors, most of which are based upon a hydroxyethylamine template. Uniquely, it possesses an aza-peptide motif but maintains many similar pharmacophore elements including lipophilic moieties that presumably bind to S2, S1, S′1 , and S′2 positions. Atazanavir is pseudo-symmetric about the central template, incorporating D-tert-Leucine at both termini. This compound is synthesized in about seven steps, with a key coupling of the chiral epoxide (derived from phenylalanine and imparting one chiral center) and N-tert-boc-N′-(4-[2-pyridyl]benzyl)hydrazine. Removal of both tert-Boc groups and double acylation with methoxycarbonyl-tert-Leucine provides the product. Another synthesis of atazanavir entails ten steps and utilizes α-(tert-bocamino) phenylpropanal as a chiral intermediate. It is a potent inhibitor of indinavir-resistant and saquinavir-resistant strains of HIV-1 (IC50=0.03–0.1 and 0.04–0.1 μM, respectively). In 300 patients who had failed previous treatment, atazanavir (400 mg once daily) was compared to lopinavir (400 mg twice daily) and ritonavir (100 mg); both arms additionally receiving two non-reverse transcriptase inhibitors. After 24 weeks, HIV RNA levels of <400 copies/mL were noted in 61% of patients receiving atazanavir and 81% of those taking lopinavir/ritonavir. After 96 weeks of therapy with atazanavir, HIV RNA copy levels were found to be <400 and <50 in 80 and 58% of patients, respectively. A study of the cross-resistance profile relative to other protease inhibitors using a panel of 551 clinical isolates (without prior atazanavir exposure but with cross-resistance to one or two other protease inhibitors; the majority had resistance to nelfinavir) showed that greater than 80% retained susceptibility to atazanavir. All of the resistant isolates from patients taking atazanavir had an I50 L substitution. The recommended dosage of atazanavir is 400 mg once daily. It has a mean half-life range of 7.9–6.5 h with about 60% bioavailability and moderate plasma protein binding (86% albumin and 89% alpha-1- acid glycoprotein (AAG)). Atazanavir was well tolerated in clinical studies and it displayed minimal lipid modulation when tested in combination with two non-reverse transcriptase inhibitors. Atazanavir had no effect on total cholesterol, low-density lipoprotein, and triglyceride levels when compared with other protease inhibitors that caused sustained elevations in these lipid levels.

Chemical Properties

Crystalline Solid

Originator

Novartis (US)

Uses

Atazanavir is a novel azapeptide protease inhibitor (PI)

Uses

enzyme inhibitor

Uses

Atazanavir is a novel azapeptide HIV protease inhibitor (PI). Antiviral.

Uses

Atazanavir is an inhibitor of HIV-1 protease (EC50 = 2.6 nM). In isolated cells, it has additive to moderately synergistic antiviral effects when combined with other antiretroviral drugs. As a result, it is commonly used in vivo in combination therapy for HIV-1 infection. Atazanavir competitively inhibits UDP-gluronosyltransferase, which conjugates bilirubin for clearance, leading to hyperbilirubinemia in a significant portion of those receiving atazanavir therapy.

Definition

ChEBI: A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).

brand name

Reyataz (Bristol-Myers Squibb).

Acquired resistance

Mutations at positions 50 (I50L), 84 (I84V) and 88 (N88S) of the protease gene are associated with resistance.

General Description

Atazanavir is an antiretroviral agent that has been approvedby the FDA for use in combination with other anti-RTagents for the treatment of HIV infections. The drug is alwaysused in combination with RT inhibitors.

Pharmaceutical Applications

An azapeptide formulated as the sulfate for oral use.

Mechanism of action

Atazanavir is dosed orally once daily, thus reducing "pill burden," and it appears to have minimal impact on lipid parameters but does increase total bilirubin. The drug is well absorbed when administered orally with food (bioavailability, ~68%). The drug is highly bound to plasma protein (86%) and is metabolized by CYP3A isoenzyme. Atazanavir is a moderate inhibitor of CYP3A, and potential drug–drug interactions are possible with CYP3A inhibitors and inducers.

Pharmacokinetics

Oral absorption: c. 68%
Cmax 400 mg once daily: c. 3.15 μg/L
300 mg + ritonavir 100 mg once daily: c. 4.47 μg/L
Cmin 400 mg once daily: c. 0.27 μg/L
300 mg + ritonavir 100 mg once daily: c. 0.65 μg/L
Plasma half-life: c. 8.6 h (300 mg+ ritonavir 100 mg)
Volume of distribution: c. Not known/available
Plasma protein binding: c. 86%
Absorption
Administration with food enhances bioavailability and reduces pharmacokinetic variability. Absorption is dependent on gastric pH. It should be given separately from proton-pump inhibitors or H2-receptor antagonists. Buffered or entericcoated formulations should be given (with food) 2 h before or 1 h after co-administration of didanosine.
Distribution
It penetrates moderately well into the CNS. The semen:plasma ratio is 0.11–4.42. It is distributed into breast milk.
Metabolism
It is extensively metabolized by CYP3A4. Administration with ritonavir prevents metabolization and enhances the pharmacokinetic profile.
Excretion
Following a single 400 mg dose, 79% and 13% of the dose was recovered in the feces and urine, respectively. It should be used with caution in the presence of mild hepatic impairment and should not be used in patients with more severe hepatic impairment.

Clinical Use

Treatment of HIV infection (in combination with other antiretroviral drugs)

Side effects

The most common adverse reactions (≥2%) are nausea, jaundice/ scleral icterus, rash, headache, abdominal pain, vomiting, insomnia, peripheral neurological symptoms, dizziness, myalgia, diarrhea, depression and fever.

Atazanavir Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Atazanavir Suppliers

Wuhan Runzeweiye Technology Co., Ltd.
Tel
027-50779735-
Fax
027-50779735
Email
runzeweiye999@163.com;
Country
China
ProdList
804
Advantage
55
J & K SCIENTIFIC LTD.
Tel
010-82848833- ;010-82848833-
Fax
86-10-82849933
Email
jkinfo@jkchemical.com;market6@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Alabiochem Tech.Co., Ltd.
Tel
0512-58900862;0512-56727736
Fax
0086-512-56765862
Email
sales@alabiochem.com;sales@alabiochem.com
Country
China
ProdList
1005
Advantage
59
Chembest Research Laboratories Limited
Tel
021-20908456-
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
5948
Advantage
61
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32358
Advantage
50
China DongFan Chemical Co.,LTD
Tel
86-0571-85151182
Fax
86-0571-85151182
Email
sales@dongfan-chem.com
Country
China
ProdList
5702
Advantage
66
XiaoGan ShenYuan ChemPharm co,ltd
Tel
0712-2580635- ;0712-2580635
Email
1791901229@qq.com;1791901229@qq.com;
Country
China
ProdList
8939
Advantage
52
ChemShuttle, Inc.
Tel
0510-83588313-802
Email
sales@chemshuttle.com
Country
China
ProdList
2281
Advantage
62
BOC Sciences
Tel
Email
info@bocsci.com
Country
United States
ProdList
9942
Advantage
65
Wuhan Fortuna Chemical Co., Ltd
Tel
027-59207852-
Fax
QQ3130921841
Email
buy@fortunachem.com
Country
China
ProdList
2957
Advantage
58
More
Less

View Lastest Price from Atazanavir manufacturers

Wuhan wingroup Pharmaceutical Co., Ltd
Product
Atazanavir 198904-31-3
Price
US $10.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
1000MT/Month
Release date
2021-07-16
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Atazanavir 198904-31-3
Price
US $0.00/Kg/Bag
Min. Order
1KG
Purity
99%min
Supply Ability
100KGS
Release date
2021-07-14
Zhuozhou Wenxi import and Export Co., Ltd
Product
Atazanavir 198904-31-3
Price
US $15.00-10.00/KG
Min. Order
1KG
Purity
99%+ HPLC
Supply Ability
Monthly supply of 1 ton
Release date
2021-07-10

198904-31-3, AtazanavirRelated Search:


  • CS-534
  • BMS-232632-05; REYATAZ;BMS23263205
  • CS-2210
  • BMS 232632 - Atazanavir | CGP 73547
  • atazanvir
  • Atazanavir, >=99%
  • Atazanavir Enantiomer
  • Atazanavir Isomer Impurity
  • Atazanavir Isomer Impurity 1
  • Atazanavir Isomer Impurity 2
  • Atazanavir Isomer Impurity 3
  • Atazanavir Intermediate Impurity 1
  • Atazanavir Intermediate Impurity 2
  • Atazanavir Intermediate Impurity 4
  • methyl((5S,10S,11S,14S)-11-benzyl-5-(tert-butyl)-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,8,12-tetraazahexadecan-14-yl)carbamate
  • Methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]a
  • EOS-60363
  • Atazanavir Intermediate Impurity 3
  • Atazanavir
  • (3S,8S, 9S, 12S)-2,5,6,13-Pentaazatetradecanedioic Acid
  • 3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-dimethyl Ester
  • Methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-[(4-pyridin-2-ylphenyl)methyl]amino]-1-phenylbutan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
  • (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide
  • 229975-97-7 (Sulfate 1:1)
  • Aids057755
  • Aids-057755
  • Atv
  • Atazanavir & Atazanavir Sulfate
  • BMS-232632(Atazanavir)
  • Atazanavir(BMS-232632)
  • Methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(MethoxycarbonylaMino)-
  • ATAZANAVIR, BISULFATE SALT
  • Atazanavir free base
  • Atazanavir iMpurity
  • 2,5,6,10,13-Pentaazatetradecanedioicacid,3,12-bis(1,1-diMethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylMethyl)-6-[[4-(2-pyridinyl)phenyl]Methyl]-,1,14-diMethyl ester, (3S,8S,9S,12S)-
  • Atazanavir Base
  • Latazanavir
  • Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12,di-tert-butyl-8-hydroxy-4,11-dioxo-6-(p-2-pyridylbenzyl)-2,5,6,10,13-pentaazatetradecanedioate
  • 1,14-Dimethyl (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate
  • Atazanavir USP/EP/BP
  • Atazanavir (10mM in DMSO)
  • 198904-31-3
  • C38H52N6O7
  • Inhibitor
  • peptides
  • API
  • All Inhibitors
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Chiral Reagents